Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

Potential Mechanisms of Cancer-Related Hypercoagulability

(2020) Nicola J. Nasser et al.   Cancers

Pharmacological cancer treatment and venous thromboembolism risk

(2020) Andrés J Muñoz Martín et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

(2020) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer

(2020) Michela Giustozzi et al.   THROMBOSIS AND HAEMOSTASIS

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

(2019) Stavros V Konstantinides et al.   EUROPEAN HEART JOURNAL

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

(2019) Dominique Farge et al.   LANCET ONCOLOGY

Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy

(2018) Akihisa Mitani et al.   ANTI-CANCER DRUGS

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

(2018) Jan Steffel et al.   EUROPACE

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

(2018) Annie M. Young et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH

(2018) A. A. Khorana et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug–drug interactions

(2018) Hanno Riess et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

(2018) Cecilia Becattini et al.   THROMBOSIS AND HAEMOSTASIS

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

(2018) Michael B. Streiff et al.   Journal of the National Comprehensive Cancer Network

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer

(2017) Anja Katholing et al.   THROMBOSIS AND HAEMOSTASIS

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents

(2015) Christopher M. Tully et al.   CANCER

Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban

(2015) C. Stöllberger et al.   HERZ

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

(2013) Thomayant Prueksaritanont et al.   AAPS Journal